Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

The Oxford Vaccine Group, led by Prof Andrew Pollard, is renowned for collaborating with Oxford’s Jenner Institute in ...

Investing.com -- AIM ImmunoTech (NYSE: AIM) Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This move is part of AIM's antiviral ...

In June 2007, AstraZeneca completed the acquisition of vaccine maker MedImmune ... right patient, right safety and right commercial. ‘Right patient’, for example, is about finding the patient ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

COVID Vaccines Linked to Autoimmune Disease** In a groundbreaking development, recent research has unveiled that COVID-19 vaccines may act as a trigger for ...

AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...

AstraZeneca have not stated plans for an alternative. An FT report meanwhile said that vaccines were “off strategy” for AstraZeneca, suggesting “figures on both sides of the negotiations hav ...

The boss of drugmaker AstraZeneca has said he was ‘very disappointed’ with the firm’s move to scrap plans for a £450 million vaccine plant in Liverpool, but insisted the business case did ...

AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site - Pascal Soriot, chief executive of AstraZeneca, ...

AstraZeneca's chief, Pascal Soriot, has said he is "very disappointed" after scapping plans for a £450m vaccine plant in Liverpool, but stressed that the numbers just didn't add up. The CEO of ...